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ABSTRACT
Infectious agents, including the BK polyomavirus (BKPyV), have been proposed 
as important inflammatory pathogens in prostate cancer. Here, we evaluated whether 
the preoperative antibody response to BKPyV large T antigen (LTag) and viral capsid 
protein 1 (VP1) was associated with the risk of biochemical recurrence in 226 
patients undergoing radical prostatectomy for primary prostate cancer. Essentially, 
the multivariate Cox regression analysis revealed that preoperative seropositivity to 
BKPyV LTag significantly reduced the risk of biochemical recurrence, independently 
of established predictors of biochemical recurrence such as tumor stage, Gleason 
score and surgical margin status. The predictive accuracy of the regression model 
was denotatively increased by the inclusion of the BKPyV LTag serostatus. In 
contrast, the VP1 serostatus was of no prognostic value. Finally, the BKPyV LTag 
serostatus was associated with a peculiar cytokine gene expression profile upon 
assessment of the cellular immune response elicited by LTag. Taken together, our 
findings suggest that the BKPyV LTag serology may serve as a prognostic factor in 
prostate cancer. If validated in additional studies, this biomarker may allow for better 
treatment decisions after radical prostatectomy. Finally, the favorable outcome of 
LTag seropositive patients may provide a potential opportunity for novel therapeutic 
approaches targeting a viral antigen.
INTRODUCTION
Prostate cancer is the most commonly diagnosed 
solid malignancy among males in western countries 
(233’000 estimated new cases in 2014 in the US) [1]. 
Currently established prognostic clinicopathologic 
parameters insufficiently differentiate between indolent 
and aggressive prostate cancer, leading to both over- and 
undertreatment of this disease [2]. Hence, an increasing 
amount of gene and protein biomarkers are considered 
for a more individualized risk stratification, but their 
implementation in routine clinical practice is still under 
evaluation [3, 4]. Therefore, a novel biomarker addressing 
an established model of prostate carcinogenesis might 
serve as a clinically valuable prognostic factor and could 
uncover a therapeutic target allowing for an effective 
tumor control.
Chronic inflammation is considered to be one of the 
main factors contributing to prostate cancer development 
[5]. Among other inflammatory-related infectious agents, 
the human BK polyomavirus (BKPyV) has been proposed 
as an important pathogen involved in the transition of 
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normal prostate glands towards overt prostate cancer 
[6]. This virus is ubiquitous in the human population and 
establishes a persistent asymptomatic infection in the 
urinary tract [7]. BKPyV replication is orchestrated by the 
viral regulatory protein large T antigen (LTag) and leads to 
lysis of permissive cells with the release of viral progeny. 
Such a lytic productive infection elicits an antibody 
response to the viral capsid protein 1 (VP1) in most 
healthy humans [8]. In the case of an abortive infection – 
where LTag expression is uncoupled from VP1 expression 
– LTag still exerts a substantial host cell stimulation that 
may transform into oncogenic activity by binding products 
of tumor suppressor genes, such as p53 and retinoblastoma 
proteins (pRB) [9]. In the context of the latter event, an 
antibody response against LTag can be elicited.
Investigating the antibody response to both BKPyV 
VP1 and LTag in prostate cancer patients could clarify the 
role of these antigens as key targets of cancer immune 
surveillance. In this study, we evaluated biochemical 
recurrence free survival (RFS) – as defined by the rate of 
patients without prostate specific antigen (PSA) relapse 
over time after radical prostatectomy (RP) – according to 
the preoperative BKPyV serostatus of primary prostate 
cancer patients. In addition, we verified the specificity of 
the antibody response to BKPyV LTag by analyzing the 
cell-mediated immune response to this antigen in selected 
patients. The final aim was to evaluate BKPyV serology 
as a potential prognostic biomarker for prostate cancer 
recurrence.
RESULTS
All of the 206 patients available for analysis had an 
adenocarcinoma of the prostate and their clinicopathologic 
characteristics are summarized in Supplementary Table 
S1. In two patients, no prostate cancer was found in the 
prostatectomy specimen (pTx), although positive prostate 
biopsies were confirmed.
The immunoglobulin G (IgG) serological assay 
results and the selected cutoffs differentiating VP1 
seronegative  from (VP1-) seropositive patients (VP1+) 
as well as the cutoffs differentiating LTag seronegative 
(LTag-), borderline LTag seropositive (LTag+) and 
strongly LTag seropositive patients (LTag++) are reported 
in Figure 1. The LTag-cutoffs were defined as the 50th and 
the 75th percentile of all the LTag IgG ratio values (1.0226 
and 1.1478, respectively), corresponding to the closest 
quartile to a ratio of 1 and to the next highest quartile, 
respectively. Accordingly, 159/206 (77%) patients were 
VP1+ (Fig. 1A), 52/206 (25%) LTag+ and 51/206 (25%) 
LTag++ (Fig. 1B). No association was found between VP1 
and LTag serostatus (Table 1). When only VP1 and LTag 
seropositive patients were considered (n = 78), a trend for 
Figure 1: Antibody activity against BKPyV VP1 and LTag in patients who underwent RP for primary prostate cancer 
(n = 206). (A) Column scatter graph of the VP1 IgG optical density values at 492 nm (OD492). The established cutoff (OD492 = 0.11) 
defining VP1 seropositivity (VP1+) was marked by a red dashed line. (B) Column scatter graph of the LTag IgG OD492 ratio values. 
Following cutoffs defined LTag seropositivity: overall 50th percentile (P50) OD492 ratio (1.0226) for borderline seropositive patients (LTag+) 
and overall 75th percentile (P75) OD492 ratio (1.1478) for strongly seropositive patients (LTag++) (red dashed lines). (C) Scatter plot 
correlating VP1 and LTag IgG activity. Quadrants were generated according to the selected VP1 and LTag cutoffs (red dashed lines). 
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a moderate correlation between VP1 and LTag activity was 
found (Spearman’s rho = 0.22, p = 0.05) (Fig. 1C).
The contingency table analysis did not provide any 
evidence for an association between the BKPyV serostatus 
and the clinicopathologic parameters (age at operation, 
PSA at diagnosis, tumor stage, nodal status, Gleason score 
and surgical margin status), other than a trend for a low 
proportion of Gleason score 5-6 in the LTag+ group and 
for a low proportion of Gleason score 8-9 in the LTag++ 
group (Table 2).
To search for an association between BKPyV 
serostatus and the clinical course of the disease after 
RP, we performed survival analyses based on time to 
biochemical recurrence (BR). To ensure the quality of our 
follow-up data, we analyzed the estimates of RFS before 
and after stratification for established predictors of BR. 
Over a median follow-up of 48 months (range = 13–70), a 
BR was documented in 43 patients. The overall estimated 
RFS was 87% (95% confidence interval [CI], 83–92) at 
24 months and 77% (95% CI, 71–84) at 48 months after 
surgery (Supplementary Fig. S1). High tumor stage, 
high Gleason score and positive surgical margins were 
associated with significantly lower estimates of RFS (p < 
0.001, p < 0.001 and p = 0.001, respectively), whereas no 
significant difference in the estimates of RFS was found 
for PSA stratification (p = 0.31) (Supplementary Fig. S2).
For VP1 serostatus stratification, no significant 
difference in the estimates of RFS was found (p = 0.96) 
(Fig. 2A). Higher IgG activity cutoffs, differentiating 
patients with a stronger antibody response to VP1, did not 
reveal any significant differences either (Supplementary 
Fig. S3). By contrast, LTag+ and LTag++ patients showed 
significantly higher estimates of RFS than LTag- patients 
(p = 0.007) (Fig. 2B). Notably, the estimated RFS at 48 
months was 89% (95% CI, 79–99) for LTag++ patients, 
85% (95% CI, 75–95) for LTag+ patients and 68% (95% 
CI, 57–78) for LTag- patients.
To further evaluate the predictive accuracy of the 
BKPyV VP1 and LTag serological assays for BR, time-
dependent receiver operating characteristic (ROC) curve 
analyses were performed based on RFS at 12, 24, 36 
and 48 months after surgery. For the VP1 IgG assay, the 
95% CI of the area under the curve (AUC) persistently 
included the 0.50 limit, thus revealing no evidence for a 
prognostic potential (Fig. 3A). For the LTag IgG assay, the 
AUC reached 0.68 (95% CI, 0.57–0.79) at 48 months (Fig. 
3B). The predictive accuracy of established predictors of 
BR yielded similar results; at 48 months, the AUC was 
0.68 (95% CI, 0.57–0.78) for tumor stage, 0.67 (95% CI, 
0.58-0.76) for Gleason score, 0.63 (95% CI, 0.54–0.73) 
for surgical margin status and 0.57 (95% CI, 46–69) for 
PSA level at diagnosis (Supplementary Fig. S4).
In the multivariate analysis, LTag+ and LTag++ 
patients maintained a significantly lower risk of BR than 
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Figure 2: Kaplan-Meier estimates of RFS by BKPyV serostatus in patients who underwent RP for primary prostate 
cancer. (A) Estimates of RFS stratified by the established cutoff for VP1 seropositivity (OD492 = 0.11) (black line = VP1- and red line = 
VP1+). (B) Estimates of RFS stratified by the 50th and the 75th percentile LTag IgG OD492 ratio (1.0226 and 1.1478, respectively) (grey line 
= LTag++, black line = LTag+ and red line = LTag-). All p values were two-sided log-rank tests.
Figure 3: Evaluation of the predictive accuracy of the BKPyV serological assays based on estimates of RFS in patients 
who underwent RP for primary prostate cancer. (A) Time-dependent ROC curves for the VP1 IgG assay prediction of BR at 12, 
24, 36 and 48 months after surgery. Curves were calculated based on continuous VP1 IgG activity levels, with the established cutoff (OD492 
= 0.11) symbolized by a red square. (B) Time-dependent ROC curves for the LTag IgG assay prediction of BR at 12, 24, 36 and 48 months 
after surgery. Curves were calculated based on continuous LTag IgG activity levels, with the overall 50th percentile LTag IgG OD492 ratio 
(1.0226) and the overall 75th percentile LTag IgG OD492 ratio (1.1478) cutoff symbolized by a red circle and a red triangle, respectively.
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LTag- patients, independent of established predictors 
of this event (tumor stage, Gleason score and surgical 
margin status) (Table 3). The predictive accuracy of the 
Cox regression model – as quantified by the Harrell’s 
concordance index – could be increased from 0.76 (95% 
CI, 0.68 – 0.83) to 0.79 (95% CI, 0.71 – 0.86) before 
and after inclusion of the BKPyV serostatus variable, 
respectively. PSA and VP1 serostatus did not reach 
the entry level criterion for the forward-stepwise Cox 
regression model and these parameters were therefore not 
included in the multivariate analysis.
The favorable prognosis of LTag seropositive 
patients prompted us to verify a finding that we previously 
reported, namely that the LTag serostatus was associated 
with a peculiar cellular immune response profile upon 
LTag antigen stimulation. For this purpose, we selected 
12 age-, stage- and grade-matched patients with the 
aim of having 4 patients per LTag serostatus group (i.e. 
LTag-, LTag+ and LTag++). Patients’ peripheral blood 
mononuclear cells (PBMCs) were ex vivo stimulated 
either with a BKPyV LTag peptide pool or with a CEF 
(cytomegalovirus, Epstein-Barr virus and influenza virus) 
peptide pool for the analysis of the gene expression of 
three specific cytokines: interferon gamma (IFN-γ), 
interleukin 10 (IL-10) and transforming growth factor β1 
(TGF-β1). Comparisons were made between the group of 
LTag seronegative patients (LTag-, n = 4) and the group 
of LTag seropositive patients (LTag+/++, n = 8) (Fig. 
4A). After LTag peptide pool stimulation, no evidence 
for differing IFN-γ gene expression levels was found 
between the LTag- group and the LTag+/++ group (p = 
1.00). Notably, the LTag+/++ group showed significantly 
higher IL-10 gene expression levels than the LTag- group 
(p = 0.008), while higher TGF-β1 gene expression levels 
were observed in the LTag- group (p = 0.11) (Fig. 4A). 
In contrast, the CEF peptide pool stimulation showed no 
evidence for differing cytokine gene expression levels 
upon BKPyV LTag serostatus stratification (Fig. 4A).
To verify whether the observed ex vivo cellular 
immune responses of these 12 patients were indeed 
Figure 4: Cytokine gene expression upon peptide pool stimulation of PBMCs from 12 selected age-, stage- and grade-
matched prostate cancer patients. (A) Box-and-whiskers plots comparing the IFN-γ, IL-10 and TGF-β1 gene expression levels 
between LTag seronegative patients (LTag-) and LTag borderline seropositive and strongly seropositive patients (LTag+/++) upon either 
LTag or CEF peptide pool stimulation. (B) Box-and-whiskers plots comparing the IFN-γ, IL-10 and TGF-β1 gene expression levels upon 
either LTag or CEF peptide pool stimulation in the group of LTag seronegative patients (LTag-) and in the group of LTag borderline 
seropositive and strongly seropositive patients (LTag+/++). Distributions of cytokine gene expression levels variables were compared by 
Mann-Whitney U tests. All p values were two-sided.
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specific to the BKPyV LTag, we compared the cytokine 
gene expression patterns induced by either the LTag or the 
CEF peptide pool. In both the LTag- and the LTag+/++ 
group, the CEF peptide pool stimulation induced 
considerably higher IFN-γ gene expression levels than the 
LTag peptide pool stimulation (p = 0.03 and p < 0.001, 
respectively) (Fig. 4B). Furthermore, after CEF peptide 
pool stimulation of the PBMCs from LTag+/++ patients, 
the IL-10 gene expression levels remained significantly 
lower than after LTag peptide pool stimulation (p = 0.003) 
(Fig. 4B). This confirms that the IL-10 elevation observed 
in LTag+/++ patients is indeed specific to the LTag peptide 
pool stimulation. Finally, in the LTag- group, a trend 
towards a higher TGF-β1 gene expression upon LTag-
peptide pool stimulation was found (p = 0.03) (Fig. 4B).
DISCUSSION
Cumulative evidence for a co-factorial role of 
the BKPyV in prostate carcinogenesis has emerged 
from prostate tissue analyses and immune response 
characterization studies in prostate cancer patients [10-
12]. To our knowledge, this is the first study addressing 
the prognostic significance of the antibody response to 
BKPyV in prostate cancer patients.
In comparison to Merkel cell carcinoma patients, 
where high Merkel cell polyomavirus VP1 IgG levels were 
associated with a better progression-free survival [13], 
no evidence for an association between the BKPyV VP1 
serostatus and the risk of prostate cancer recurrence was 
provided in this study. This finding underlines the notion 
that a productive BKPyV infection – leading to a strong 
VP1 IgG activity – is unlikely to reflect the oncogenic 
potential of the BKPyV, as permissive cells will be lysed 
upon release of the viral progeny [14].
Rather, the novelty of our investigation is the 
finding that an antibody response to the viral regulatory 
protein LTag is associated with the clinical course of 
prostate cancer patients after RP. Because the LTag may 
lead to the oncogenic transformation of BKPyV infected 
glandular prostate cells, an increased antibody activity 
against this oncogenic protein would be expected in cases 
with high risk of BR. Indeed, in cervical cancer patients, 
antibodies against human papillomavirus proteins E6 and 
E7, whose functions are similar to LTag, are markers of 
worse prognosis [15]. Differently, in this study, increasing 
estimates of RFS were found over increasing levels of 
preoperative BKPyV LTag IgG activity. Particularly, 
about 89% of all strongly LTag seropositive patients 
were free of BR at 48 months after RP, whereas only 
68% of all LTag seronegative patients were BR-free at 48 
months. This finding was highlighted in the multivariate 
analysis adjusting for the usually available patient 
clinicopathologic characteristics, which indicated that 
the risk of BR was lowered by at least 29% in strongly 
LTag seropositive patients and that even borderline 
seropositivity for BKPyV LTag led to a risk reduction of 
at least 7%. Of note, the addition of the BKPyV serostatus 
variable in the multivariate Cox regression model resulted 
in a denotative increase of the predictive accuracy of the 
model, thus suggesting the preoperative BKPyV serostatus 
as a potentially valuable biomarker for the prediction of 
BR after RP.
The almost equal distribution of the VP1 serostatus 
over the three levels of the LTag serostatus reveals that 
more than half of all VP1 seronegative patients must have 
had LTag antigens exposed to their immune system in the 
absence of a VP1 antigenic stimulation. This exemplifies 
that the uncoupled continuous expression of LTag with the 
lacking VP1 expression, typically occurring in abortively 
infected cells, can be effectively targeted by the immune 
system. However, to date, it is unknown whether the 
prostate is the main site for the antigenic exposition of 
BKPyV LTag to the immune system and the detection 
of LTag in areas of overt prostate cancer remains elusive 
and needs to be standardized [16]. Several studies 
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regarding the association between BKPyV and prostate 
cancer led to the common conclusion that the virus 
exerts its oncogenic activity at early stages of cancer 
development [10]. Particularly, LTag has frequently been 
detected in areas of proliferative inflammation atrophy 
(PIA), which is considered a precursor lesion leading 
to prostatic intraepithelial neoplasia and overt prostate 
cancer [17]. The absence of any association between the 
BKPyV serostatus and the usual patient clinicopathologic 
characteristics, such as tumor stage or Gleason score, 
underlines the concept that BKPyV has an etiological 
role only in precancerous and early stage cancer lesions 
surrounding tumor areas.
The cytoplasmic localization of LTag in complex 
with wild type p53 in abortively infected cells, as seen 
at the PIA level [10, 18], makes this antigen a suitable 
target for the generation of memory CD8+ and CD4+ T 
cells. Indeed, reactivation of HLA class I effector memory 
CD8+ T cells and class II polyfunctional CD4+ T cells with 
dual T-helper and T-cytotoxic properties was observed 
in BKPyV seropositive healthy subjects experiencing 
smoldering infections [19-21]. Furthermore, peculiar 
cellular immune response profile was recalled by the LTag 
stimulation of PBMCs in BKPyV seropositive prostate 
cancer patients [11].
Correspondingly, we assessed the cytokine gene 
expression of PBMCs upon ex vivo LTag peptide pool 
stimulation and could verify our previous findings. 
Notably, we were able to recall a strong IL-10 gene 
expression in LTag seropositive patients and additionally 
characterized a trend for an increased TGF-β1 gene 
expression in LTag seronegative patients. Both IL-10 and 
TGF-β1 are characteristic of type 1 T regulatory cells and 
are frequently reported as immunoregulatory cytokines 
impairing cancer immune surveillance [22-24]. Yet, IL-
10 has also been found to induce effective antitumor 
immune responses in various studies [25]. The latter might 
explain why the LTag peptide pool stimulation would 
recall the expression of IL-10 in the favorable prognosis 
group of LTag seropositive patients. Hence, a favorable 
microenvironment allowing for effective immune-
mediated tumor surveillance would explain the long-
lasting absence of BR in most patients showing strong 
LTag seropositivity enrolled in this study.
We could verify the PBMCs’ ability to recall a 
strong IFN-γ immune response upon stimulation with the 
immunogenic CEF peptide pool. In addition, no evidence 
for a significant increase in IL-10 or TGF-β1 cytokine 
gene expression levels was found after CEF peptide pool 
stimulation. This was in agreement with our expectations, 
as the CEF peptide pool is used for its ability to recall 
effector immune responses and stimulates CD8+ T cells 
to preferentially produce IFN-γ. Hereby, we not only 
attributed the specificity of our findings to the BKPyV, 
but also verified that the individual variability of the 
LTag-specific antibody activity was not due to individual 
differences of age-related decline of immune functions. 
The relative immunological integrity of the evaluated 
cohort is further attested by the overall VP1 seroprevalence 
of 77%, which is in agreement with previous age-stratified 
seroepidemiological studies on polyomaviruses in blood 
donors [26, 27].
On account of these findings, the elicitation of a 
functional immune response against the BKPyV LTag 
by therapeutic means might increase the amount of 
specific prostate-infiltrating T lymphocytes with effector 
functions or redirect existing effector T cells with an 
exhausted phenotype, thereby inducing a favorable local 
tumor immune microenvironment allowing for immune-
mediated tumor surveillance and consequently lower the 
risk of BR after RP [28].
Although more than 200 prostate cancer patients 
were tested for BKPyV serostatus using subtype 1/b1 for 
VP1-based virus-like particles (VLP) generation – which 
is the most common BKPyV subtype among Caucasians 
[29] – the present study is not devoid of limitations. 
Particularly, patients’ ethnicity and antigenically distinct 
BKPyV serotypes might represent possible confounding 
factors of our estimates of RFS [30, 31]. Moreover, a 
potential LTag-specific antibody cross-reactivity between 
the BKPyV and other human polyomaviruses – such as 
the endemic JC Polyomavirus (JCPyV) – might have 
contributed to the LTag IgG ratio values [32]. However, 
so far, no rationale for a role of polyomavirures other than 
the BKPyV has been demonstrated in prostate cancer [33]. 
Notably, in our prior investigations, we could not find 
any JCPyV-specific LTag sequences at indicative copy 
numbers in prostatic tissues, whereas BKPyV-specific 
LTag sequences were readily detectable in 42% of the 
PCa tissue specimens and 32% of the benign prostatic 
hyperplasia tissues [11]. Based on the findings reported 
by Βodaghi et al., the rise of IgG activity levels against 
BKPyV-specific LTag subdomain 1 (LTD1) is preceded 
by an extensive BKPyV viremia in immunocompromised 
kidney transplanted patient [34]. Accordingly, we 
consider it most plausible to assume that the IgG activity 
observed in our investigation reflects BKPyV LTag 
exposure to the immune system. Additional studies on 
human polyomaviruses’ LTag IgG seroprevalence and its 
distribution over age groups in healthy populations would 
be needed for clarification.
Another limitation of our study is the absence 
of evidence for an association between the PSA levels 
at diagnosis and the risk of BR, the former being an 
established risk-predictor. This might be related to the 
relatively short follow-up or to the intrinsic imprecisions 
of PSA measurements, which were not standardized. 
Nevertheless, our findings are based on a representative 
prostate cancer patient cohort undergoing RP, as reflected 
by the significant and independent performance of 
other established predictors of BR, such as tumor stage, 
Gleason score and surgical margin status. Hence, the 
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reported results are intriguing enough to justify further 
characterization of the role of BKPyV in prostate cancer.
In conclusion, our investigation provides an 
unprecedented epidemiological evidence for an association 
between antibody responses to BKPyV LTag and the 
clinical course of prostate cancer. Particularly, we reveal 
that the preoperative LTag serology may be a valuable 
biomarker for the prediction of favorable prostate cancer 
prognosis after RP. If validated in additional studies, this 
biomarker may allow for better postoperative treatment 
decisions. Finally, this study suggests a promising 
opportunity for novel therapeutic approaches targeting a 
virus-related oncogenic antigen in early prostate cancer 
lesions.
METHODS
 Study population
We evaluated a case series of 226 patients 
undergoing RP for primary prostate cancer in our 
institution between October 2007 and November 2011. 
A prospective observational tumor marker study design 
was used, according to Simon et al. [35]. Whole-mount 
prostatectomy sections were analyzed by the Institute of 
Surgical Pathology of the University Hospital of Zurich. 
Tumor grades and stages were assigned according to the 
International Society of Urological Pathology (ISUP 2005) 
[36] and Union for International Cancer Control (UICC 
2002 and 2009) [37, 38], respectively. When no prostate 
cancer was found in the prostatectomy specimen (pTx), 
Gleason score at biopsy was reported. None of the patients 
had received neoadjuvant androgen-deprivation therapy.
The primary endpoint was time from surgery to 
BR, with censoring of patients without BR at the date of 
last follow-up. For this purpose, patients were routinely 
assessed by PSA measurements at 6 weeks, 3, 6 and 12 
months postoperatively and annually thereafter. BR was 
defined as a rise in PSA levels ≥0.1 ng/mL after surgery. 
Serum PSA level testing was not standardized, since 
many patients were initially diagnosed and followed up 
in referral centers. Overall, 20 patients unfit for survival 
analyses were excluded for the following reasons: i) 
postoperative PSA measurements not available (n = 4); 
ii) postoperative PSA nadir (PSA level drop <0.1 ng/mL) 
not reached (n = 13); iii) administration of a second-line 
therapy at PSA levels <0.1 ng/mL (n = 3). Local ethics 
committee approval and written informed consent from 
all patients were provided. This study was conducted 
following the Reporting Recommendations for Tumor 
Marker Prognostic Studies (REMARK) guidelines [39].
Blood specimen collection and handling 
Blood specimens were collected before surgery. 
Serum tubes were centrifuged at 1300 x g for 10 min at 
room temperature. After centrifugation, serum specimens 
(1 mL aliquots) were frozen within 2 hours after collection 
and stored at -80°C until use. PBMCs were isolated 
from venous blood by Ficoll-Hypaque density gradient 
centrifugation (Histopaque, Sigma-Aldrich, St. Louis, 
MO, USA) and stored in liquid nitrogen until use.
Serological analysis
Serological assays were performed blinded to the 
patients’ characteristics and outcome. Antibody responses 
to BKPyV were measured by enzyme immunoassays 
(EIA) based on two BKPyV antigens: the VP1 in the 
form of VLP and the N-terminal 133-aa LTag subdomain 
1 (LTD1) conjugated with glutathione-S-transferase 
(GST-LTD1 fusion protein). These two antigens were 
produced as described previously [34]. Briefly, VLP were 
isolated from Spodoptera frugiperda Sf9 cells (American 
Type Culture Collection [ATCC], Manassas, VA, USA) 
infected with recombinant baculovirus encoding BKPyV 
subtype 1/b1 VP1 (Bac-to-Bac baculovirus expression 
system, Invitrogen, Carlsbad, CA, USA). Infected Sf9 
cells were disrupted by sonication and glass mortar and 
pestle treatment. VLP were purified from cellular lysate 
by CsCl gradient. The 3-dimensional conformation of VLP 
was confirmed by transmission electron microscopy. For 
LTD1 expression, the recombinant baculovirus transfer 
plasmid was ligated with a pFastBac1-GST vector 
(Invitrogen, Carlsbad, CA, USA) allowing for single-
step GST-fusion protein purification by glutathione-
affinity chromatography (Glutathione Sepharose 4B, GE 
Healthcare, Piscataway, NJ, USA). Purified non-VLP 
expressing cell lysates and purified GST were used as 
negative controls.
After coating EIA wells with 100 ng of VLP or 25 
ng of GST-LTD1 fusion proteins, BKPyV-specific VP1 or 
LTag IgG activity, respectively, was measured as an optical 
density value at 492 nm (OD492) with a serum dilution of 
1:400 using an automated plate reader (Tecan Group Ltd., 
Männedorf, Switzerland), as described previously [34]. 
For each antigen, all serum samples were analyzed on 
the same day. For VP1 IgG, we adopted the cutoff OD492 
= 0.11 after subtraction of purified non-VLP expressing 
cell lysates OD492 value (negative control) to differentiate 
seronegative (VP1-) from seropositive patients (VP1+), 
as established elsewhere [8, 34, 40, 41]. For LTag IgG, 
the ratio of the GST-LTD1 IgG OD492 value divided by 
its respective affinity-purified GST IgG OD492 value 
(negative control) was calculated for each patient. This 
allowed for normalization of inter-individual variations of 
unspecific IgG binding to GST. Ideally, an LTag IgG ratio 
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of >1 would define a patient as seropositive. Therefore – 
and since a standard cutoff for the LTag IgG activity had 
not been defined at the time of this study execution –, we 
considered the quartile of all LTag IgG OD492 ratio values 
closest to a ratio of 1 to differentiate between seronegative 
(LTag-) and borderline seropositive patients (LTag+) 
and the next highest quartile to discriminate strongly 
seropositive (LTag++) patients. This allowed for specific 
comparisons between seronegative (LTag-), borderline 
seropositive (LTag+) and strongly seropositive patients 
(LTag++).
Ex vivo induction and cytokine gene expression by 
qRT-PCR
After thawing, PBMCs were stimulated with either 
a BKPyV LTag peptide pool, a positive control CEF 
(cytomegalovirus, Epstein-Barr virus and influenza virus) 
peptide pool, or a negative control HIV peptide pool (JPT 
Peptide Technology, Berlin, Germany), as previously 
described [11]. Quantitative gene amplification was 
performed by using a Corbett Rotor-Gene 3000 Instrument 
(Corbett Life Science, Sydney, Australia) with a TaqMan 
Universal PCR master mix reagents kit and “on demand” 
sets of primers and probes for cytokine gene expression of 
IFN-γ, IL-10 and TGF-β1 (Applied Biosystems, Rotkreuz, 
Switzerland), as previously described [42]. The negative 
control was used to compute cytokine gene expression 
fold changes. Finally, the normalized data were analyzed 
by the 2-∆∆Ct method using β-Actin as an endogenous 
reference gene [43].
Statistical analysis
Categorical variables were evaluated by contingency 
table analyses and Pearson Chi-square tests or Fisher’s 
exact tests, as appropriate. Mann-Whitney U tests were run 
to determine differences between continuous independent 
variables. Association between continuous variables was 
assessed by Spearman’s rank correlation coefficient. 
Estimates of RFS were calculated with the Kaplan-
Meier method and were compared with the log-rank test. 
Based on these estimates of RFS, the predictive accuracy 
of the considered BKPyV seromarkers was evaluated 
by time-dependent ROC curves. A forward-stepwise 
multivariate Cox regression analysis (entry level at 0.05) 
was modeled to evaluate the antibody response to BKPyV 
as a predictor of BR, adjusting for established predictors 
of BR. Proportional hazard assumption was assessed for 
each variable with the plot of a log-negative-log survival 
distribution and by the plot of Schoenfeld’s residuals over 
time. The predictive accuracy of the Cox regression model 
was estimated using the Harrell’s concordance index. 
Owing to multiple comparisons, the two-sided significance 
level was set at 0.01, exception made for the multivariate 
Cox regression analysis. The latter represents a single 
test that includes confounding covariates, justifying a 
significance level of 0.05.
Column scatter graphs were generated with 
GraphPad Prism 5.04 (GraphPad Software, La Jolla CA, 
USA). Time-dependent ROC curves were estimated with 
the timeROC v0.2 package for R [44]. The Harrell’s 
concordance index was based on forward-stepwise 
multivariate Cox regression analysis results using Stata 
13.1 (Stata Corp., College Station, TX, USA). Analyses 
of all other variables were performed with IBM SPSS 
Statistics 22.0 (IBM Corp., Armond, NY, USA).
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